Cargando…

Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route

Protein therapeutics is playing an increasingly critical role in treatment of human diseases. However, current vectors are captured by the digestive endo-lysosomal system, which results in an extremely low fraction (<2%) of protein being released in the cytoplasm. This paper reports a drug-delive...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Xiaofei, Teng, Chao, Du, Xiaoqing, Lv, Yaiqi, Xiao, Qingqing, Wu, Yubing, He, Wei, Yin, Lifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037042/
https://www.ncbi.nlm.nih.gov/pubmed/30026860
http://dx.doi.org/10.7150/thno.23804
_version_ 1783338269736435712
author Xin, Xiaofei
Teng, Chao
Du, Xiaoqing
Lv, Yaiqi
Xiao, Qingqing
Wu, Yubing
He, Wei
Yin, Lifang
author_facet Xin, Xiaofei
Teng, Chao
Du, Xiaoqing
Lv, Yaiqi
Xiao, Qingqing
Wu, Yubing
He, Wei
Yin, Lifang
author_sort Xin, Xiaofei
collection PubMed
description Protein therapeutics is playing an increasingly critical role in treatment of human diseases. However, current vectors are captured by the digestive endo-lysosomal system, which results in an extremely low fraction (<2%) of protein being released in the cytoplasm. This paper reports a drug-delivering-drug platform (HA-PNPplex, 200 nm) for potent intracellular delivery of protein and combined treatment of cancer. Methods: The platform was prepared by loading functional protein on pure drug nanoparticles (PNPs) followed by hyaluronic acid coating and was characterized by dynamic light scattering, transmission electron microscopy, and gel electrophoresis. In vitro, cellular uptake, trafficking, and cytotoxicity were evaluated by flow cytometry and confocal laser microscopy. Protein expression was assayed by western blot. In vivo, blood circulation and biodistribution were studied using a fluorescence imaging system, antitumor efficacy was assessed in a caspase 3-deficient tumor model, and biocompatibility was determined by comparison of hemolytic activity and proinflammatory cytokines and tissue histology. Results: HA-PNPplex delivered the functional protein, caspase 3, to cells via bypassing endo-lysosomes and raised the caspase-3 level 6.5-fold in caspase 3-deficient cells. Promoted tumor accumulation (1.5-fold) and penetration were exhibited, demonstrating a high tumor-targeting ability of HA-PNPplex. HA-PNPplex rendered a 7-fold increase in caspase 3 in tumor and allowed for a 100% tumor growth inhibition and >60% apoptosis, implying significant antitumor activities. Conclusions: This platform gains cellular entry without entrapment in the endo-lysosomes and enables efficient intracellular protein delivery and resultant profound cancer treatment. This platform, with extremely high drug-loading, is a valuable platform for combined cancer therapy with small-molecule drugs and proteins. More importantly, this work offers a robust and safe approach for protein therapeutics and intracellular delivery of other functional peptides, as well as gene-based therapy.
format Online
Article
Text
id pubmed-6037042
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-60370422018-07-19 Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route Xin, Xiaofei Teng, Chao Du, Xiaoqing Lv, Yaiqi Xiao, Qingqing Wu, Yubing He, Wei Yin, Lifang Theranostics Research Paper Protein therapeutics is playing an increasingly critical role in treatment of human diseases. However, current vectors are captured by the digestive endo-lysosomal system, which results in an extremely low fraction (<2%) of protein being released in the cytoplasm. This paper reports a drug-delivering-drug platform (HA-PNPplex, 200 nm) for potent intracellular delivery of protein and combined treatment of cancer. Methods: The platform was prepared by loading functional protein on pure drug nanoparticles (PNPs) followed by hyaluronic acid coating and was characterized by dynamic light scattering, transmission electron microscopy, and gel electrophoresis. In vitro, cellular uptake, trafficking, and cytotoxicity were evaluated by flow cytometry and confocal laser microscopy. Protein expression was assayed by western blot. In vivo, blood circulation and biodistribution were studied using a fluorescence imaging system, antitumor efficacy was assessed in a caspase 3-deficient tumor model, and biocompatibility was determined by comparison of hemolytic activity and proinflammatory cytokines and tissue histology. Results: HA-PNPplex delivered the functional protein, caspase 3, to cells via bypassing endo-lysosomes and raised the caspase-3 level 6.5-fold in caspase 3-deficient cells. Promoted tumor accumulation (1.5-fold) and penetration were exhibited, demonstrating a high tumor-targeting ability of HA-PNPplex. HA-PNPplex rendered a 7-fold increase in caspase 3 in tumor and allowed for a 100% tumor growth inhibition and >60% apoptosis, implying significant antitumor activities. Conclusions: This platform gains cellular entry without entrapment in the endo-lysosomes and enables efficient intracellular protein delivery and resultant profound cancer treatment. This platform, with extremely high drug-loading, is a valuable platform for combined cancer therapy with small-molecule drugs and proteins. More importantly, this work offers a robust and safe approach for protein therapeutics and intracellular delivery of other functional peptides, as well as gene-based therapy. Ivyspring International Publisher 2018-06-06 /pmc/articles/PMC6037042/ /pubmed/30026860 http://dx.doi.org/10.7150/thno.23804 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Xin, Xiaofei
Teng, Chao
Du, Xiaoqing
Lv, Yaiqi
Xiao, Qingqing
Wu, Yubing
He, Wei
Yin, Lifang
Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route
title Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route
title_full Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route
title_fullStr Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route
title_full_unstemmed Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route
title_short Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route
title_sort drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037042/
https://www.ncbi.nlm.nih.gov/pubmed/30026860
http://dx.doi.org/10.7150/thno.23804
work_keys_str_mv AT xinxiaofei drugdeliveringdrugplatformmediatedpotentproteintherapeuticsviaanonendolysosomalroute
AT tengchao drugdeliveringdrugplatformmediatedpotentproteintherapeuticsviaanonendolysosomalroute
AT duxiaoqing drugdeliveringdrugplatformmediatedpotentproteintherapeuticsviaanonendolysosomalroute
AT lvyaiqi drugdeliveringdrugplatformmediatedpotentproteintherapeuticsviaanonendolysosomalroute
AT xiaoqingqing drugdeliveringdrugplatformmediatedpotentproteintherapeuticsviaanonendolysosomalroute
AT wuyubing drugdeliveringdrugplatformmediatedpotentproteintherapeuticsviaanonendolysosomalroute
AT hewei drugdeliveringdrugplatformmediatedpotentproteintherapeuticsviaanonendolysosomalroute
AT yinlifang drugdeliveringdrugplatformmediatedpotentproteintherapeuticsviaanonendolysosomalroute